High dose cyclophosphamide in HLAhaploidentical

Size: px
Start display at page:

Download "High dose cyclophosphamide in HLAhaploidentical"

Transcription

1 High dose cyclophosphamide in HLAhaploidentical stem cell transplantation Ephraim J. Fuchs, M.D., M.B.A. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

2 Alternative Donor Transplantation: An Unmet Need HLA-matched related donors are available in only 25-30% of cases Outcomes of MRD and 10/10 matched URD transplantation similar Alternative donor options include cord blood, haploidentical related donor and mismatched URD donor transplantation Studies are underway to compare the risks and benefits of transplantation from these donor sources 25% of allogeneic transplant worldwide are now from haploidentical donors

3 Cyclophosphamide-induced tolerance Proliferating ALLOREACTIVE cells are killed anti-cmv anti-cmv anti-hsv anti-hsv Non-proliferating non-alloreactive cells are spared

4 Cyclophosphamide (Cy)-induced tolerance to minor H antigens 50 million CBA spleen cells IV Cy 200 mg/kg IP B10.BR mouse hrs. B10.BR (H-2 k ) CBA (H-2 k ) 8 wks 1 year B10.BR tolerant of CBA

5 Mixed chimerism across full MHC barrier using Fludarabine, 200 cgy TBI, and PTCy 6 months post-bmt MHC-mismatched BMT Conditioned, no BMT

6 Treatment schema (n=374) Treatment in outpatient department! Median age: 55 (18-75); 132 patients (35%) >60 years Median mismatch: 4/10 (0-5) Disease risk index: Low 19% (n=72); Intermediate 65% (n=242); High 16% (n=60) Disease type: Myeloid 32% (n=120); Lymphoid 67% (n=249)

7 Mini-haploBMT with PTCy: outcomes

8 Haplos have caught up to matched *R Szydlo et al. J Clin Oncol 15: , 1997 Personal communication with P. Armand (n=614) S McCurdy et al. Blood 125: , year progression-free survival, stratified by disease risk index Matched Haplo Disease stage/ risk 1997* (matched sib) 2015 (sib + MUD) 1997* 2015 Early/low risk Intermediate Advanced/high risk

9 Parallel Phase 2 Trials Using Partially HLA-MM Related Bone Marrow or Unrelated ducb Grafts Brunstein CG, Fuchs EJ, Carther SL, et al. Blood 2011; 118: CTN Study: 2 Parallel Multicenter Phase 2 Studies 56% AML (cord), 44% AML (haplo) RIC Regimen of FLU/CY/ Low dose TBI for both groups Early TRM higher with UCBT (24% vs 7%) but relapse rate lower (31% vs 45%) UCBT 1 year OS 54%, PFS 46% Haplo-BMT 1 year OS 62%, PFS 48%

10 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (ducb) versus HLA-Haploidentical Related Bone Marrow (haplo-bm) for Patients with Hematologic Malignancies BMT CTN PROTOCOL 1101 CEA VERSION 4.0 Study Team Scott Ramsey, M.D., Ph.D. Paul O Donnell, M.D., Ph.D. Parent Study Collaborators Ephraim Fuchs, M.D. Paul O Donnell, M.D., Ph.D. Claudio Brunstein, M.D. Mary Eapen, M.D.

11 Haploidentical Transplantation with Post-Transplantation Cyclophosphamide Compared with HLA-Matched Related or Unrelated Donor Transplantion for Patients 50 years Blaise D, et al. BBMT 2016; 22: Age 55 AML + MDS: 48% (haplo) 40% (MRD), 48% (URD) Grades II-IV agvhd higher after URD HCT (44% vs 23% and 21%) No severe cgvhd after haplo vs 16% (MRD) and 14% (URD) PFS NRM 3-fold higher after URD SCT Conclusion: OS, PFS and severe cgvhd same after haplo and MRD HCT but superior to URD HCT Severe cgvhd Free and PFS

12 Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide Compared With 10/10 Allele-Matched Unrelated and HLA-Identical Sibling Donors Transplanmtion Bashey A, et al. BBMT 2016: 22: MDS+AML: Haplo (43%), 10/10 URD (51%) MRD (47%) HCT NRM and relapse same Grades II-IV agvhd same for haplo and MRD but < URD Less moderate-severe cgvhd after haplo compared to URD and MRD HCT DFS same between the three groups, OS similar after haplo and URD HCT but < MRD HCT

13 RIC Haplo-HCT vs Matched URD HCT for Lymphoma Kanate AS, et al. Blood 2016; 127: CIBMTR retrospective comparison N=917 (185 haplo, 241 URD with ATG, 491 URD w/o ATG) agvhd, NRM, relapse, PFS, OS equivalent among the 3 groups URD HCT cgvhd incidence > than haplo HCT Conclusion: Haplo-HCT = URD HCT for lymphoma except for less cgvhd agvhd: NS cgvhd: p<.007

14 Big increase in number of haplos % change from 2010 Matched sib % Haplo % Matched unrelated % Mismatched unrelated % Cord % TOTALS %

15 Ethnic minorities in the US have a hard time finding a matched donor Likelihood of identifying an unrelated donor (%) 8/8 HLA match 7/8 HLA match Likelihood of identifying a cord blood unit for patients >20 years (%) 6/6 HLA match >5/6 HLA match >4/6 HLA match White European African-American Chinese Hispanic South or Central American

16 Haplos fill MUD deficit in African-Americans Caucasians Graft source % of 2014 total African-Americans % of 2014 total Matched sib % % Haplo % % Matched unrelated % % Mismatched unrelated % % Unrelated cord blood % % Totals % %

17 HLA-haploidentical BMT plus posttransplantation cyclophopshamide for non-malignant disorders

18 HaploBMT for non-malignant diseases Summary Disease N Full donor chimerism Graft failure GVHD Death Sickle cell (41%) 12 (35%) 4 (12%) 1 (3%) Aplastic anemia (100%) 0 (0%) 1 (9%) 0 (0%) Totals (56%) 14 (31%) 5 (11%) 1 (2%)

19 Mini-BMT for sickle cell disease (SCD) Treatment schema None 400 cgy TBI prep

20 HaploBMT for sickle cell disease Overall outcomes Regimen Full donor Mixed chimera Graft failure GVHD Mini-haplo with PT/Cy Add ATG days ATG, tacro rapamycin ATG, rapa, G-CSF stim donor (1 fatal) ATG, 400 cgy TBI, rapamycin Matched sibs Haplo totals (n=34) Totals (n=38) All complete chimeras are able to discontinue immunosuppression at 1 year post-bmt Overall: 65% cure, 35% graft failure, 10% GVHD, 4% mortality

21 HaploBMT + PTCy for aplastic anemia ATG ATG ATG Flu Cy Flu Cy Flu Flu Flu GVHD Prophylaxis: Tacrolimus, MMF, & Post-HSCT Cy TBI Cy Cy G-CSF-stimulated bone marrow IV Flu Cy Cy = Fludarabine 30 mg/m 2 IV daily = Cyclophosphamide 14.5 mg/kg IV daily TBI = 200 cgy = Cyclophosphamide 50 mg/kg IV daily ATG = Thymoglobulin 0.5 mg/kg (day-9) & 2 mg/kg (day -8,-7)

22 Hopkins Haplo BMT for Aplastic Anemia Age/ Sex Pre-BMT Therapy Degree of HLA match Day of engraftm ent (ANC >1000) Last donor chimerism agvhd cghvd Response Follow- Up (mos) 35M ATG/ CsA 5/ none none CR 48 52M ATG/ CsA 5/ none none CR 25 45F ATG/ CsA 5/ Gr 2 skin Gr 2 skin CR 20 27F ATG 5/ none none CR 14 33M HiCY 5/ none none CR 16 17M HiCY 5/ none none CR 8 54M ATG/ CsA 5/ none none CR 10 26F ATG/ CsA/TPO 5/ none none CR 12 59M ATG/CsA? none none CR 7 20F ATG/CsA? none none CR 6 11M ATG/CsA? none none CR 6 25F HiCY MUD none none NE 2 Summary: 12 pts, 12 full donor, 11 CR, 1 GVHD (8%)

23 New haplo initiatives in the USA

24 BMT CTN 1502: Aplastic Anemia Haploidentical Cohort ATG ATG ATG Flu Cy Flu Cy Flu Flu Flu GVHD Prophylaxis: Tacrolimus, MMF, & Post-HSCT Cy TBI Cy Cy Flu Cy Cy = Fludarabine 30 mg/m 2 IV daily = Cyclophosphamide 14.5 mg/kg IV daily TBI = 200 cgy = Cyclophosphamide 50 mg/kg IV daily ATG = Thymoglobulin 0.5 mg/kg (day-9) & 2 mg/kg (day -8,-7) 24

25 Reduced Intensity Conditioning before HLA-Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease BMT CTN protocol development Michael R. DeBaun MD MPH Adetola Kassim, MD Mark Walters, MD Robert Brodsky, MD

26 Haplo-ID BMT for SCD - Hopkins Conditioning regimen ATG, CPM 14.5 mg/kg x 2, Flu, TBI 200cGy with post-bmt CPM Replaced tacrolimus with sirolimus to avoid posterior reversible encephalopathy syndrome 29 consecutive patients treated First cohort; 8/14 (57%) engrafted Second cohort; 10/15 (67%) engrafted Overall engraftment 62% with 97% survival Bolanos-Meade J et al, Blood 22:4285, 2012 and Brodsky R, et al. Foundation for sickle cell disease research meeting, Miami. April 2014.

27 Combined HLA-haploidentical bone marrow and kidney transplantation to achieve immunosuppression-free transplantation tolerance Prednisone Patient #1: 29 yo with IgA nephropathy, now 4.3 months out from combined transplant full donor chimerism, gr II skin GVHD, Cr 1.4

28 Sequential, related donor partial liver transplantation followed by BMT for hepatocellular carcinoma* Patient with HCC confined to liver but outside Milan criteria (single tumor <5 cm or <3 tumors, each <3 cm) *Sponsored by the Fibrolamellar Cancer Foundation

29 Immunotherapy of HPV-associated cancer Treatment schema Clinical trial objectives Determine maximally tolerated dose of donor lymphocytes Document toxicities of transplantation and post-transplant donor lymphocyte infusions (DLI) Characterize immune and clinical responses to transplantation and to DLI

30 HaploSCT in the United States Summary Fastest growth in numbers of all graft sources Near universal donor availability, low cost Fills an unmet need for ethnic minorities Post-transplantation cyclophosphamide is the dominant method of GVHD prophylaxis Low rates of acute and chronic GVHD and non-relapse mortality Haplo plus PTCy outcomes are as good as those after cord blood or HLA-matched unrelated donor SCT New national initiatives to treat sickle cell disease and aplastic anemia using haplosct with PTCy PTCy lowers toxicity of haplobmt to enable combined solid organ/ bone marrow transplants, or treatment of solid tumors

31 Acknowledgements BMT Physicians Rick Jones Leo Luznik Chris Kanakry Shannon McCurdy Yvette Kasamon Javier Bolaños-Meade Lode Swinnen Oncology Biostatistics Gary Rosner Mariana Zahurak Fuchs lab Leo Luznik Heather Symons Han-Hsuan Fu Jie Wang BMT Patients

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

Haploidentical Donor Transplants: Outcomes and Comparison to Other. Paul V. O Donnell BSBMT Education Day London 12 October 2011

Haploidentical Donor Transplants: Outcomes and Comparison to Other. Paul V. O Donnell BSBMT Education Day London 12 October 2011 Haploidentical Donor Transplants: Outcomes and Comparison to Other Donor Types Paul V. O Donnell BSBMT Education Day London 12 October 2011 Clinical Problem: Identification of a Donor for Allogeneic Transplantation

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Haploidentical Transplantation today: and the alternatives

Haploidentical Transplantation today: and the alternatives Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks

More information

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest

More information

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

Stem Cell Transplantation

Stem Cell Transplantation Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor

More information

Trapianto allogenico

Trapianto allogenico POST ASH 2013: 3 Workshop Regionale Marchigiano 28 Febbraio - 1 Marzo 2014 Hotel Domus Stella Maris, ANCONA REPORT OF THE BEST ASH NEWS Trapianto allogenico Dr. Claudio Giardini U.O. Ematologia e Centro

More information

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

AML:Transplant or ChemoTherapy?

AML:Transplant or ChemoTherapy? AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens

More information

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891

More information

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de

More information

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize

More information

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide REGULAR ARTICLE Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Rob Wynn RMCH & University of Manchester, UK. HCT in Children Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action

More information

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD. Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific

More information

Umbilical Cord Blood Transplantation

Umbilical Cord Blood Transplantation Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor

More information

A G E N D A CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Salt Lake City, UT Thursday, February 22, 2018, 2:45 4:45 pm

A G E N D A CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Salt Lake City, UT Thursday, February 22, 2018, 2:45 4:45 pm 2. Accrual 3. Presentations, Not for publication or presentation A G E N D A CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Salt Lake City, UT Thursday, February 22, 2018, 2:45 4:45 pm Co-Chair:

More information

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell

More information

Hematopoietic Stem Cell Transplant for Sickle Cell Anemia: The changing landscape

Hematopoietic Stem Cell Transplant for Sickle Cell Anemia: The changing landscape Hematopoietic Stem Cell Transplant for Sickle Cell Anemia: The changing landscape Adetola A. Kassim, MD, MS Associate Professor of Medicine Hematology/Stem cell Transplant Vanderbilt University Medical

More information

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011

More information

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,

More information

AIH, Marseille 30/09/06

AIH, Marseille 30/09/06 ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille

More information

Hematopoietic Stem Cell Transplantation for Fanconi Anemia

Hematopoietic Stem Cell Transplantation for Fanconi Anemia Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential

More information

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear

More information

Latest results of sibling HSCT in acquired AA. Jakob R Passweg

Latest results of sibling HSCT in acquired AA. Jakob R Passweg Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and

More information

Related haploidentical donors versus matched unrelated donors

Related haploidentical donors versus matched unrelated donors Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG

T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG UCT T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG Nicolas Novitzky PhD, FCP(SA) Engraftment variables in Allo SCT Host HLA identity Integrity of marrow stroma Disease type and status Previous chemotherapy Graft

More information

Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology

Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology Advances in Autologous and Allogeneic Stem Cell Transplantation Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology April 12, 2014 Disclosures

More information

HLA Haploidentical Transplantation:

HLA Haploidentical Transplantation: HLA Haploidentical Transplantation: The Journey to the Transplantation For All Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine King Chulalongkorn Memorial Hospital Disclosure No relevant

More information

RIC in Allogeneic Stem Cell Transplantation

RIC in Allogeneic Stem Cell Transplantation RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants

More information

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives

More information

Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate

Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute

More information

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation

More information

Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016

Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016 Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain

More information

Acute GVHD. ESH-EBMT 2009 Latimer A. Devergie

Acute GVHD. ESH-EBMT 2009 Latimer A. Devergie Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier

More information

Disclosure. Objectives 1/22/2015

Disclosure. Objectives 1/22/2015 Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North

More information

EBMT 2017 Satellite Symposium

EBMT 2017 Satellite Symposium SAVING LIVES WITH INNOVATIVE CELL-BASED THERAPY EBMT 2017 Satellite Symposium Sunday March 26th Time: 11:00-12:30 Room: Les Goudes 2 Advances in Haploidentical Stem Cell Transplantation and Post Transplant

More information

An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide

An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide CRITICAL REVIEW An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide AJH Munira Shabbir-Moosajee, 1 Lindsey Lombardi, 2 and Stefan

More information

Review Article Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies

Review Article Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies Advances in Hematology Volume 2016, Article ID 3905907, 16 pages http://dx.doi.org/10.1155/2016/3905907 Review Article Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies Kevon

More information

Hematopoietic Stem Cell Transplant in Adults with Sickle Cell Disease: the changing landscape

Hematopoietic Stem Cell Transplant in Adults with Sickle Cell Disease: the changing landscape Hematopoietic Stem Cell Transplant in Adults with Sickle Cell Disease: the changing landscape Adetola Kassim, M.D. Associate Professor of Medicine Vanderbilt-Meharry-Matthew Walker Center of Excellence

More information

Back to the Future: The Resurgence of Bone Marrow??

Back to the Future: The Resurgence of Bone Marrow?? Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow

More information

Haploidente HSCT bei Sichelzellkrankheit. Selim Corbacioglu Regensburg, Germany

Haploidente HSCT bei Sichelzellkrankheit. Selim Corbacioglu Regensburg, Germany Haploidente HSCT bei Sichelzellkrankheit Selim Corbacioglu Regensburg, Germany Hemoglobinopathies are the largest patient population with an absolute indication for SCT 5% of the world s popula2on are

More information

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, 1 Julie Aldridge, 2 Haesook T. Kim, 2 Karen K. Ballen, 1 Corey

More information

Il Trapianto da donatore MUD. Alessandro Rambaldi

Il Trapianto da donatore MUD. Alessandro Rambaldi Il Trapianto da donatore MUD Alessandro Rambaldi Overview Comparison of outcomes of allo- HSCT from matched related and unrelated donors. We need evidence based results! Is the Dme needed to find an unrelated

More information

Samples Available for Recipient and Donor

Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,

More information

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals

More information

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples 4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone

More information

HCT for Myelofibrosis

HCT for Myelofibrosis Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

EBMT Complications and Quality of Life Working Party Educational Course

EBMT Complications and Quality of Life Working Party Educational Course EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) PROTOCOL 15-MMUD Version 1.0 May 18, 2016

Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) PROTOCOL 15-MMUD Version 1.0 May 18, 2016 A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies Resource for Clinical

More information

In-vitro T-cell Depletion is Not Necessary for Haplo-identical Transplantation

In-vitro T-cell Depletion is Not Necessary for Haplo-identical Transplantation In-vitro T-cell Depletion is Not Necessary for Haplo-identical Transplantation Xiao-Jun Huang M.D. Peking University Institute of Hematology (PUIH), Peking University People s Hospital, Beijing Key Laboratory

More information

Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes

Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes The The 44 th th WBMT WBMT SYMPOSIUM 2017 2017 Riyadh, Saudi Saudi Arabia Arabia Mouhab Mouhab Ayas, Ayas, MD MD Department of Pediatric

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction

More information

Review of Stem Cell Collection Data 2016 Ronan Foley, Professor, Director Stem Cell Laboratory, McMaster University

Review of Stem Cell Collection Data 2016 Ronan Foley, Professor, Director Stem Cell Laboratory, McMaster University 1 Review of Stem Cell Collection Data 2016 Ronan Foley, Professor, Director Stem Cell Laboratory, McMaster University Objectives 2 Review our national apheresis-based stem cell registry To evaluate the

More information

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017 2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:

More information

The question is not whether or not to deplete T-cells, but how to deplete which T-cells

The question is not whether or not to deplete T-cells, but how to deplete which T-cells The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative

More information

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) PROTOCOL 15-MMUD Version 3.0 October 25, 2017

Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) PROTOCOL 15-MMUD Version 3.0 October 25, 2017 A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Patients with Hematologic Malignancies Resource for Clinical

More information

Treatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota

Treatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota Treatment of Chronic Graft versus Host Disease Daniel Weisdorf MD University of Minnesota October 2013 Infections Transplant Events d-8 0 1mo 3mo 6mo Conditioning Transplant Engraftment Mucositis Organ

More information

Objectives. Cord Blood is RelaOvely Recent Technology BMT Pharmacists Conference: Debate - Haploidentical vs. Umbilical Cord Blood Transplant

Objectives. Cord Blood is RelaOvely Recent Technology BMT Pharmacists Conference: Debate - Haploidentical vs. Umbilical Cord Blood Transplant 214 BMT Pharmacists Conference: Debate - Haploidentical vs. Umbilical Cord Blood Transplant Claudio G Brunstein Associate Professor of Medicine University of Minnesota Minneapolis, MN Objectives Defend

More information

Donor derived CD19 specific CAR + T cell therapy after haploidentical hematopoietic stem cell transplantation Laurence J.N. Cooper Hyatt Orlando

Donor derived CD19 specific CAR + T cell therapy after haploidentical hematopoietic stem cell transplantation Laurence J.N. Cooper Hyatt Orlando Donor derived CD19 specific CAR + T cell therapy after haploidentical hematopoietic stem cell transplantation Laurence J.N. Cooper Hyatt Orlando International Airport Hotel December 3, 2015 (afternoon)

More information

Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche

Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale

More information

COHEM Barcellona 2012 Hemoglobinopathies debate

COHEM Barcellona 2012 Hemoglobinopathies debate COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication

More information

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1 Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,

More information

Post Transplant Management for Sickle Cell. Title

Post Transplant Management for Sickle Cell. Title Post Transplant Management for Sickle Cell Title Kimberly Kasow, DO October 14, 2016 Thank you for this opportunity to present this information I have no financial interests to disclose. Goal of Transplant

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University

Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against

More information

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation

More information

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants

More information

Symposium Summary Fourth Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 19-20, 2006

Symposium Summary Fourth Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 19-20, 2006 Biology of Blood and Marrow Transplantation 12:1206-1217 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1211-0001$32.00/0 doi:10.1016/j.bbmt.2006.08.030 Symposium Summary

More information

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

Hematopoietic Cell Transplantation for Myelofibrosis. Outline Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic

More information